CO2023014204A2 - Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) - Google Patents
Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)Info
- Publication number
- CO2023014204A2 CO2023014204A2 CONC2023/0014204A CO2023014204A CO2023014204A2 CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2 CO 2023014204 A CO2023014204 A CO 2023014204A CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2
- Authority
- CO
- Colombia
- Prior art keywords
- nek7
- inhibitors
- never
- compounds
- related kinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000011278 mitosis Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 abstract 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable del mismo, en donde A, X, Y, Z, R1, R 2, R3 y n son como se definen en la presente. También se proporcionan métodos asociados con la preparación y uso de estos compuestos, composiciones farmacéuticas que comprenden estos compuestos y métodos para modular la actividad del inflamasoma NLRP3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163170708P | 2021-04-05 | 2021-04-05 | |
US202163185282P | 2021-05-06 | 2021-05-06 | |
PCT/US2022/023443 WO2022216680A1 (en) | 2021-04-05 | 2022-04-05 | Nek7 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023014204A2 true CO2023014204A2 (es) | 2023-11-10 |
Family
ID=81448482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0014204A CO2023014204A2 (es) | 2021-04-05 | 2023-10-24 | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4320127A1 (es) |
JP (1) | JP2024513227A (es) |
KR (1) | KR20230175222A (es) |
AU (1) | AU2022255486A1 (es) |
BR (1) | BR112023019435A2 (es) |
CA (1) | CA3214042A1 (es) |
CO (1) | CO2023014204A2 (es) |
IL (1) | IL307258A (es) |
WO (1) | WO2022216680A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240158394A1 (en) * | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
WO2006066174A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
WO2008046802A1 (en) | 2006-10-16 | 2008-04-24 | Novartis Ag | Phenylacetamides useful as protein kinase inhibitors |
EP2170871A2 (en) | 2007-06-26 | 2010-04-07 | GlaxoSmithKline LLC | Processes for preparing benzimidazole thiophenes |
UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
CA2867760C (en) | 2012-04-04 | 2021-10-05 | Rigel Pharmaceuticals, Inc. | Indolizinyl derivatives as protein kinase c inhibitors and uses thereof |
WO2013170770A1 (zh) | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
JP6186434B2 (ja) | 2012-07-18 | 2017-08-23 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体及びその医薬品への応用 |
US8859553B2 (en) | 2012-07-30 | 2014-10-14 | Astar Biotech Llc | Protein kinase inhibitors |
US9604980B2 (en) | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
CN105431436B (zh) | 2013-05-14 | 2017-11-28 | 内尔维阿诺医学科学有限公司 | 吡咯并[2,3‑d]嘧啶衍生物,它们的制备方法和它们作为激酶抑制剂的用途 |
JP6380861B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | Rafキナ−ゼおよび/またはRafキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
BR112016017997A2 (pt) | 2014-02-03 | 2017-08-08 | Quadriga Biosciences Inc | Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos |
EP3186247B1 (en) | 2014-08-26 | 2021-03-03 | Astar Biotech LLC | Protein kinase inhibitors |
CN105837575B (zh) | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
WO2017117393A1 (en) | 2015-12-30 | 2017-07-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
CN107513068A (zh) | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
US10870647B2 (en) | 2016-06-20 | 2020-12-22 | Daegu-Gyeongbuk Medical Innovation Foundation | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
KR102500416B1 (ko) | 2016-06-21 | 2023-02-17 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체 |
EP3296297A1 (en) | 2016-09-15 | 2018-03-21 | Centre National De La Recherche Scientifique | Benzimidazol derivatives for treating filovirus infection |
WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
EP3630778A1 (en) | 2017-05-26 | 2020-04-08 | Ichnos Sciences SA | Novel inhibitors of map4k1 |
WO2018222917A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
WO2019192962A1 (en) * | 2018-04-05 | 2019-10-10 | Merck Patent Gmbh | Heteroaryl compounds as type ii irak inhibitors and uses hereof |
KR102548191B1 (ko) | 2018-04-09 | 2023-06-28 | 상하이테크 유니버시티 | 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용 |
US20210139484A1 (en) | 2018-04-11 | 2021-05-13 | Gossamer Bio Services, Inc. | Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions |
TW202016109A (zh) | 2018-06-13 | 2020-05-01 | 英屬開曼群島商百濟神州有限公司 | 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途 |
WO2020135507A1 (zh) | 2018-12-26 | 2020-07-02 | 杭州百新生物医药科技有限公司 | 一种多取代苯氨基嘧啶衍生物及其制备方法和用途 |
CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
WO2020206583A1 (en) | 2019-04-08 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Kinase inhibitors and uses thereof |
AU2020355359B2 (en) * | 2019-09-26 | 2023-08-24 | Shenzhen Targetrx, Inc. | Substituted aromatic fused ring derivative and composition comprising same, and use thereof |
KR20220099958A (ko) | 2019-10-01 | 2022-07-14 | 골드핀치 바이오 인코포레이티드 | Cdk5의 치환된 1,6-나프티리딘 억제제 |
CN115210226B (zh) | 2020-02-20 | 2024-01-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
WO2021226547A2 (en) | 2020-05-08 | 2021-11-11 | Halia Therapeutics, Inc. | Targeted nek7 inhibition for modulation of the nlrp3 inflammasome |
CN113717156B (zh) | 2020-05-25 | 2023-05-09 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
GB202010464D0 (en) | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
-
2022
- 2022-04-05 WO PCT/US2022/023443 patent/WO2022216680A1/en active Application Filing
- 2022-04-05 EP EP22720127.4A patent/EP4320127A1/en active Pending
- 2022-04-05 KR KR1020237037931A patent/KR20230175222A/ko unknown
- 2022-04-05 CA CA3214042A patent/CA3214042A1/en active Pending
- 2022-04-05 IL IL307258A patent/IL307258A/en unknown
- 2022-04-05 JP JP2023561240A patent/JP2024513227A/ja active Pending
- 2022-04-05 BR BR112023019435A patent/BR112023019435A2/pt unknown
- 2022-04-05 AU AU2022255486A patent/AU2022255486A1/en active Pending
-
2023
- 2023-10-24 CO CONC2023/0014204A patent/CO2023014204A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2024513227A (ja) | 2024-03-22 |
IL307258A (en) | 2023-11-01 |
CA3214042A1 (en) | 2022-10-13 |
KR20230175222A (ko) | 2023-12-29 |
EP4320127A1 (en) | 2024-02-14 |
BR112023019435A2 (pt) | 2023-10-24 |
AU2022255486A1 (en) | 2023-10-19 |
WO2022216680A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
CL2022002695A1 (es) | Inhibidores de rip1k | |
CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
UY38998A (es) | Derivados de bencimidazol, su uso en medicina y composiciones que los contienen | |
AR127681A1 (es) | Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
CO2023012903A2 (es) | Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2) | |
CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico | |
PE20191819A1 (es) | Analogos de deutetrabenazina, su preparacion y uso | |
UY37412A (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 |